← All indications
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.
Subtype terms (1)
More specific conditions that are subtypes of Urinary Bladder Neoplasms in the MeSH hierarchy.
- Non-Muscle Invasive Bladder Neoplasms
5 drugs (1 approved, 4 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (39)
- diclofenac
- amino acids
- rocuronium
- clindamycin
- remimazolam
- ertapenem
- droperidol
- dexmedetomidine
- penpulimab
- levobupivacaine
- enfortumab vedotin
- sodium chloride
- epirubicin
- tislelizumab
- neostigmine
- solifenacin
- glycopyrronium
- acetylsalicylic acid
- alprazolam
- mebeverine
- nicotine
- levofloxacin
- pembrolizumab
- multivitamins
- lidocaine
- bupropion
- bacille calmette-guerin
- lornoxicam
- propofol
- icosapent ethyl
- +9 more
Phase 3 trials (77)
- cephalexin
- etoposide
- vinflunine
- alvimopan
- Filgrastim
- ipilimumab
- larotaxel
- n-(4-hydroxyphenyl)all-trans retinamide
- uracil
- pertuzumab
- oxygen
- carboplatin
- amoxicillin
- cg0070
- eribulin
- interferon alpha-2b
- cabozantinib
- doxorubicin
- simethicone
- aminolevulinic acid
- nalbuphine
- bms-986205
- cobalamin
- keyhole limpet hemocyanin
- cetrelimab
- atezolizumab
- apaziquone
- lapatinib
- methotrexate
- trastuzumab
- +47 more
Phase 2 trials (228)
- [177lu]lu-dpi-4452
- skb264
- osimertinib
- ascrinvacumab
- hmbd-001
- mdna11
- epacadostat
- vemurafenib
- vls-1488
- rogaratinib
- propranolol
- oc-001
- bortezomib
- Mycobacterium vaccae
- temsirolimus
- s-488210
- agen2034
- oblimersen sodium
- flucytosine
- dalteparin
- belinostat
- mln2480
- larotrectinib
- hyaluronidase (human recombinant)
- rapa-201 autologous t cells
- snk01
- shr-2005
- panitumumab
- phenylacetic acid
- fluorocyclopentenylcytosine
- +198 more
Phase 1 trials (138)
- adct-502
- mage-a3 asci
- e7766
- ro7284755
- merestinib
- bbi-355
- Fluciclovine
- tos-358
- mk-6018
- tiragolumab
- tanespimycin
- personalized neoantigen vaccine
- vinorelbine
- kf-0210
- suramin
- idov-immune
- ramucirumab
- custirsen
- clsp-1025
- mnpr-101-dfo*-89zr
- enoblituzumab
- cis-urocanic acid
- bupivacaine
- bcd-135
- vmd-928
- so-c101
- ava6000
- fulvestrant
- azacitidine
- incmga00012
- +108 more
Other trials (29)
- atropine
- enoxaparin
- bvd-523
- apixaban
- 124i-psca
- indocyanine green
- mirabegron
- 131i-lipiodol
- ringer's lactate
- [68ga]ga-nota-t4
- olive
- monosodium glutamate
- arag
- hydromorphone
- omega-3 fatty acids
- water
- Ferumoxtran
- ga-nota-rt4
- mango
- sevoflurane
- morphine
- evans blue
- neratinib maleate
- pioglitazone
- varenicline
- pacritinib
- jing-si
- desflurane
- [18f]f-resca-t4
Organizations
Organization Involved with Phase 4 Indications (14)
- Merck
- National Cancer Institute (NCI)
- Temple University
- Mansoura University
- Medical University of Warsaw
- Seoul National University
- Peking University
- Tel Aviv University
- Technion University
- University of Texas at Houston
- State University of New York, Buffalo
- General Electric
- Azienda Ospedaliera Sant'Andrea, Roma
- Ankara Yildirim Beyazıt University
Organization Involved with Phase 3 Indications (131)
- Pierre Fabre
- Abnoba
- Spectrum Pharmaceuticals
- Bristol-Myers Squibb
- Roche
- Eli Lilly
- Genzyme
- Pfizer
- Sanofi
- Allergan
- Bayer
- FKD Therapies Oy
- GlaxoSmithKline
- Handok Pharmaceuticals Co., Ltd.
- Medical Enterprises Europe B.V.
- Nippon Kayaku Co.,Ltd.
- Nektar Therapeutics
- Photocure
- Samyang Biopharmaceuticals Corporation
- Agentschap NL
- Cold Genesys, Inc.
- Intracel
- Fondazione Toscana Gabriele Monasterio
- Central European Cooperative Oncology Group
- Medical Research Council
- Aarhus University
- Atlantic Health System
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Azienda Ospedaliera San Camillo Forlanini
- Baylor University
- +101 more
Organization Involved with Phase 2 Indications (197)
- Incyte
- Cytogen
- Axcan
- Foundation Medicine
- Seattle Genetics
- Eisai
- Celgene
- Millennium Pharmaceuticals
- Amgen
- Clovis Oncology
- Genmab
- Astellas
- Imclone
- Immunomedics
- Titan Pharmaceuticals
- Merck Serono
- Exelixis
- Genentech
- MedImmune
- Sanofi-Synthelabo
- Shionogi
- Wyeth
- AIO-Studien-gGmbH
- Novartis
- Bavarian Nordic
- BeOne Medicines
- Biofabri, S.L
- Celldex Therapeutics
- Endocyte
- Halozyme Therapeutics
- +167 more
Organization Involved with Phase 1 Indications (57)
- ADC Therapeutics SARL
- Adaptimmune
- Archivel Farma S.L.
- BioCis Pharma Ltd
- Rainier Therapeutics
- Blue Earth Diagnostics
- Cell Biotech Co., Ltd.
- Cell Genesys
- FinnMedi Oy
- MacroGenics
- Oncolytics Biotech
- Pieris Pharmaceuticals GmbH
- SYZ Cell Therapy Co..
- Tocagen Inc.
- Viralytics
- PrECOG, LLC.
- British Columbia Cancer Agency
- Bnai Zion Medical Center
- Duke University
- Ludwig Institute for Cancer Research
- Ohio State University
- Shenzhen Institute for Innovation and Translational Medicine
- Southern Illinois University
- University of Lausanne
- University of Maryland
- University of Tampere
- University of Virginia
- State University of New York
- University of British Columbia
- Vancouver Coastal Health
- +27 more
Organization Involved with Other Experimental Indications (12)
- National Cancer Institute, Egypt
- Barmherzige Brüder Vienna
- CAMC Health System
- King Faisal University
- Nanjing Medical University
- Yonsei University
- General Hospital Zadar
- King Faisal Specialist Hospital
- Erciyes University
- National Research Center, Egypt
- The University of Texas, Dallas
- Urology and Nephrology Center